Binding Sites are compared using Shaper.
For more information, please see the following publication:
Desaphy J. et al. Comparison and Druggability Prediction of protein-Ligand Binding sites from pharmacophore-annotated cavity shapes J. Chem. Inf. Model., 2012, 52(8), pp2287-2299
Binding Sites are considered as similar when the similarity value is greater than 0.44
PDB ID | HET | Uniprot Name | EC Number |
---|---|---|---|
3uza | T4G | Adenosine receptor A2a |
PDB ID | HET | Uniprot Name | EC Number | Binding Site Similarity |
Align |
---|---|---|---|---|---|
3uza | T4G | Adenosine receptor A2a | / | 1.000 | |
3uzc | T4E | Adenosine receptor A2a | / | 0.642 | |
3rey | XAC | Adenosine receptor A2a | / | 0.641 | |
3rfm | CFF | Adenosine receptor A2a | / | 0.601 | |
3qak | UKA | Adenosine receptor A2a | / | 0.529 | |
3t8x | T8X | T-cell surface glycoprotein CD1b | / | 0.489 | |
1xdd | AAY | Integrin alpha-L | / | 0.481 | |
5k2d | ZMA | Adenosine receptor A2a | / | 0.477 | |
2y98 | MIV | Mycinamicin IV hydroxylase/epoxidase | / | 0.473 | |
5iua | 6DX | Adenosine receptor A2a | / | 0.470 | |
2y46 | MIV | Mycinamicin IV hydroxylase/epoxidase | / | 0.469 | |
3c0g | 3AM | Peripheral plasma membrane protein CASK | 2.7.11.1 | 0.469 | |
3l6j | Z90 | Alr2278 protein | / | 0.469 | |
2fb8 | 215 | Serine/threonine-protein kinase B-raf | 2.7.11.1 | 0.466 | |
3qpn | PFK | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | 3.1.4.17 | 0.466 | |
1q5d | EPB | Epothilone C/D epoxidase | 1.14 | 0.465 | |
4jib | 1L6 | cGMP-dependent 3',5'-cyclic phosphodiesterase | 3.1.4.17 | 0.460 | |
3p99 | LNP | Lanosterol 14-alpha-demethylase | / | 0.458 | |
3w1w | CHD | Ferrochelatase, mitochondrial | 4.99.1.1 | 0.458 | |
2ovy | PFJ | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | 3.1.4.17 | 0.457 | |
3a1l | 2CC | Cytochrome P450 | / | 0.457 | |
4iae | 1DX | Alr2278 protein | / | 0.457 | |
3eml | ZMA | Adenosine receptor A2a | / | 0.456 | |
4fk3 | 325 | Serine/threonine-protein kinase B-raf | 2.7.11.1 | 0.454 | |
3aba | FLI | Cytochrome P450 | / | 0.453 | |
4ib4 | ERM | 5-hydroxytryptamine receptor 2B | / | 0.453 | |
4bbx | LKF | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | 3.1.4.17 | 0.452 | |
4iar | ERM | 5-hydroxytryptamine receptor 1B | / | 0.452 | |
2jc6 | QPP | Calcium/calmodulin-dependent protein kinase type 1D | 2.7.11.17 | 0.450 | |
2qd4 | CHD | Ferrochelatase, mitochondrial | 4.99.1.1 | 0.450 | |
3oez | STI | Proto-oncogene tyrosine-protein kinase Src | 2.7.10.2 | 0.450 | |
1soj | IBM | cGMP-inhibited 3',5'-cyclic phosphodiesterase B | 3.1.4.17 | 0.448 | |
2po7 | CHD | Ferrochelatase, mitochondrial | 4.99.1.1 | 0.447 | |
3d3e | D3E | Corticosteroid 11-beta-dehydrogenase isozyme 1 | 1.1.1.146 | 0.447 | |
4fhf | 0TT | Spore photoproduct lyase | / | 0.447 | |
3v8w | 0G2 | Tyrosine-protein kinase ITK/TSK | 2.7.10.2 | 0.446 | |
1mkd | ZAR | cAMP-specific 3',5'-cyclic phosphodiesterase 4D | 3.1.4.53 | 0.445 | |
3qpp | PFW | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | 3.1.4.17 | 0.445 | |
4jqh | 1MF | Alr2278 protein | / | 0.445 | |
1pkf | EPD | Epothilone C/D epoxidase | 1.14 | 0.444 | |
3cr7 | PPS | Adenylyl-sulfate kinase | 2.7.1.25 | 0.444 | |
3ctj | 320 | Hepatocyte growth factor receptor | 2.7.10.1 | 0.444 | |
4mvh | 2F5 | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | 3.1.4.17 | 0.444 | |
3sn7 | 540 | cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | 3.1.4.17 | 0.443 | |
4j6c | STR | Cytochrome P450 monooxygenase | / | 0.443 | |
3u8h | BHP | Phospholipase A2, membrane associated | / | 0.442 | |
4bii | PYW | Enoyl-[acyl-carrier-protein] reductase [NADH] | 1.3.1.9 | 0.442 | |
4iah | 1DX | Alr2278 protein | / | 0.440 | |
5c6c | CMP | cGMP-dependent protein kinase 2 | 2.7.11.12 | 0.440 |